Literature DB >> 23360835

Effect of dihydrokainate on the capacity of repair of DNA damage and apoptosis induced by doxorubicin.

Sabry M Attia1, Saleh A Bakheet.   

Abstract

The intention of the current study was to investigate the effect of non-toxic doses of dihydrokainate on the capacity of repair of DNA damage and apoptosis induced by doxorubicin in mouse bone-marrow cells. The scoring of micronuclei and olive tail moment was undertaken in the current study as markers of DNA damage and repair. Apoptosis was analysed by the occurrence of a hypodiploid DNA peak. Oxidative stress markers such as bone-marrow reactive oxygen species, lipid peroxidation, reduced and oxidised glutathione were assessed as a possible mechanism underlying this amelioration. In addition, the influence of dihydrokainate on doxorubicin-induced topoisomerase II inhibition was examined. Dihydrokainate was neither genotoxic nor apoptogenic at doses equivalent to 10 or 20mg/kg/day for 7 days. Pre-treatment of mice with dihydrokainate significantly enhances the repair of doxorubicin-induced DNA damage and reduced doxorubicin-induced apoptosis depending on dose. Doxorubicin induced marked biochemical alterations characteristic of oxidative stress, including increased reactive oxygen species, enhanced lipid peroxidation and reduction in the reduced/oxidised glutathione ratio. Prior administration of dihydrokainate ahead of doxorubicin challenge ameliorated these oxidative stress markers. Importantly, dihydrokainate treatment had no antagonising effect on doxorubicin-induced topoisomerase II inhibition. Conclusively, this study provides for the first time that dihydrokainate enhances the repair of doxorubicin-induced DNA damage, which resides, at least in part, in its ability to modulate the cellular antioxidant levels. Based on our data presented, strategies can be developed to enhance the repair of doxorubicin-induced genomic damage in normal cells using dihydrokainate without diminishing doxorubicin's anti-topoisomerase II activity. Thus, improvement of doxorubicin's therapeutic index may be achieved by using dihydrokainate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360835     DOI: 10.1093/mutage/ges079

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  6 in total

1.  Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine.

Authors:  Abhishek Basu; Prosenjit Ghosh; Arin Bhattacharjee; Arup Ranjan Patra; Sudin Bhattacharya
Journal:  Mutagenesis       Date:  2015-03-16       Impact factor: 3.000

2.  Chia Seed Oil Ameliorates Doxorubicin-Induced Cardiotoxicity in Female Wistar Rats: An Electrocardiographic, Biochemical and Histopathological Approach.

Authors:  Akheruz Zaman Ahmed; Kamalesh D Mumbrekar; Shakta Mani Satyam; Prakashchandra Shetty; Melanie Rose D'Souza; Varun Kumar Singh
Journal:  Cardiovasc Toxicol       Date:  2021-03-19       Impact factor: 3.231

3.  Down-regulation of GADD45A enhances chemosensitivity in melanoma.

Authors:  Jia Liu; Guoqiang Jiang; Ping Mao; Jing Zhang; Lin Zhang; Likun Liu; Jia Wang; Lawrence Owusu; Baoyin Ren; Yawei Tang; Weiling Li
Journal:  Sci Rep       Date:  2018-03-07       Impact factor: 4.379

4.  Nano-Resveratrol: A Promising Candidate for the Treatment of Renal Toxicity Induced by Doxorubicin in Rats Through Modulation of Beclin-1 and mTOR.

Authors:  Ahlam M Alhusaini; Laila M Fadda; Abeer M Alanazi; Wedad S Sarawi; Hatun A Alomar; Hanaa M Ali; Iman H Hasan; Rehab Ahmed Ali
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

5.  miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.

Authors:  Jingpei Long; Zhiwei Ji; Kai Jiang; Zhaoyang Wang; Guanmin Meng
Journal:  Biomed Res Int       Date:  2015-10-07       Impact factor: 3.411

6.  Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.

Authors:  Haoyu Li; Zhenghu Chen; Ting Hu; Long Wang; Yang Yu; Yanling Zhao; Wenijing Sun; Shan Guan; Jonathan C Pang; Sarah E Woodfield; Qing Liu; Jianhua Yang
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.